Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

rifampicin 300mg

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

behzad pharmacy - rifampicin - capsule - 300

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

behzad pharmacy - rifampicin - capsule - 150

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - rifampicin - capsule - 150 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - rifampicin - capsule - 300 mg

India - English - Central Drugs Standard Control Organization

sanofi aventis - rifampicin,pyrazinamide,isoniazid - tab - 120,250,80;mg - 10

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

rifamoicin 60mg isoniazid 30mg pyrazinamide 150mg

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - lopinavir; ritonavir - syrup - 80 mg - lopinavir 80 mg; ritonavir 20 mg

United States - English - NLM (National Library of Medicine)

american health packaging - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 150 mg - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (eg, rifater ® 1) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, th

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 600 mg in 10 ml - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment.  since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. tuberculosis rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., rifater® ) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tube